274 related articles for article (PubMed ID: 18577155)
1. Insulin therapy in elderly patients with type 2 diabetes: the role of insulin glargine.
Janka HU
Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():35-41. PubMed ID: 18577155
[TBL] [Abstract][Full Text] [Related]
2. Improving treatment satisfaction and other patient-reported outcomes in people with type 2 diabetes: the role of once-daily insulin glargine.
Bradley C; Gilbride CJ
Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():50-65. PubMed ID: 18577157
[TBL] [Abstract][Full Text] [Related]
3. A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes.
Marbury TC; Schwartz S; Rosenberg MA; Jariwala N; Becker RH; Johnston PS
Exp Clin Endocrinol Diabetes; 2008 May; 116(5):282-8. PubMed ID: 18484560
[TBL] [Abstract][Full Text] [Related]
4. Lower severe hypoglycemia risk: insulin glargine versus NPH insulin in type 2 diabetes.
Dailey G; Strange P
Am J Manag Care; 2008 Jan; 14(1):25-30. PubMed ID: 18197742
[TBL] [Abstract][Full Text] [Related]
5. The role of new basal insulin analogues in the initiation and optimisation of insulin therapy in type 2 diabetes.
Baxter MA
Acta Diabetol; 2008 Dec; 45(4):253-68. PubMed ID: 18766296
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials.
Bazzano LA; Lee LJ; Shi L; Reynolds K; Jackson JA; Fonseca V
Diabet Med; 2008 Aug; 25(8):924-32. PubMed ID: 18959605
[TBL] [Abstract][Full Text] [Related]
7. Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study.
Hermansen K; Dornhorst A; Sreenan S
Curr Med Res Opin; 2009 Nov; 25(11):2601-8. PubMed ID: 19739940
[TBL] [Abstract][Full Text] [Related]
8. Hypoglycaemic valleys: an under-recognised problem in type 2 diabetes?
Frier BM
Int J Clin Pract Suppl; 2002 Jul; (129):12-9. PubMed ID: 12166599
[TBL] [Abstract][Full Text] [Related]
9. Comparison of glycaemic control in patients with Type 2 diabetes on basal insulin and fixed combination oral antidiabetic treatment: results of a pilot study.
De Mattia G; Laurenti O; Moretti A
Acta Diabetol; 2009 Mar; 46(1):67-73. PubMed ID: 19030772
[TBL] [Abstract][Full Text] [Related]
10. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
Resmini E; Minuto F; Colao A; Ferone D
Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
[TBL] [Abstract][Full Text] [Related]
11. An update on the long-acting insulin analogue glargine.
Thisted H; Johnsen SP; Rungby J
Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):1-11. PubMed ID: 16867163
[TBL] [Abstract][Full Text] [Related]
12. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
[TBL] [Abstract][Full Text] [Related]
13. Resource utilisation and costs in patients with type 2 diabetes mellitus treated with insulin glargine or conventional basal insulin under real-world conditions in Germany: LIVE-SPP study.
Schöffski O; Breitscheidel L; Benter U; Dippel FW; Müller M; Volk M; Pfohl M
J Med Econ; 2008; 11(4):695-712. PubMed ID: 19450076
[TBL] [Abstract][Full Text] [Related]
14. The cost-effectiveness of insulin glargine vs. neutral protamine Hagedorn insulin in type 2 diabetes: a focus on health economics.
Levin P
Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():66-75. PubMed ID: 18577158
[TBL] [Abstract][Full Text] [Related]
15. Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: a population-based study.
Donnelly LA; Morris AD; Frier BM; Ellis JD; Donnan PT; Durrant R; Band MM; Reekie G; Leese GP;
Diabet Med; 2005 Jun; 22(6):749-55. PubMed ID: 15910627
[TBL] [Abstract][Full Text] [Related]
16. Study design and baseline characteristics of patients in the PRESENT study.
Shestakova M; Bech OM; Momani MS
Diabetes Res Clin Pract; 2008 Sep; 81 Suppl 1():S3-9. PubMed ID: 18672309
[TBL] [Abstract][Full Text] [Related]
17. Early hypoglycaemia after accidental intramuscular injection of insulin glargine.
Karges B; Boehm BO; Karges W
Diabet Med; 2005 Oct; 22(10):1444-5. PubMed ID: 16176210
[TBL] [Abstract][Full Text] [Related]
18. Perceived symptoms of hypoglycaemia in elderly type 2 diabetic patients treated with insulin.
Jaap AJ; Jones GC; McCrimmon RJ; Deary IJ; Frier BM
Diabet Med; 1998 May; 15(5):398-401. PubMed ID: 9609362
[TBL] [Abstract][Full Text] [Related]
19. Medically minimising the impact of hypoglycaemia in type 2 diabetes: a review.
Noh RM; Graveling AJ; Frier BM
Expert Opin Pharmacother; 2011 Oct; 12(14):2161-75. PubMed ID: 21668402
[TBL] [Abstract][Full Text] [Related]
20. Insulin glargine: cornerstone treatment for type 2 diabetes patients. Introduction.
Garg SK
Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():1-4. PubMed ID: 18577151
[No Abstract] [Full Text] [Related]
[Next] [New Search]
